companies / avenuebiosciences-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 2,484,0002.5M | ○ |
|---|---|---|
| founded | 2023 | |
| hq | Helsinki, Finland | |
| industry | unknown | |
| stage | seed |
Machine-learning platform that engineers N-terminal signal peptides to boost protein expression yield in mammalian systems. Sold to therapeutic developers working on biologics, mRNA, biosimilars, antibodies, and vaccines. Spun out of University of Helsinki research with a $5.7M raise and BioTools Innovator selection.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-10-01 | seed | 2,484,0002.5M | null | ○ |
Cloudflare, Unpkg, Google Tag Manager, cdnjs, jquery 3.5.1
| fact | status | src |
|---|---|---|
| Seed, $2.5M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |